Search Results - "Hilger, R.‐A."

Phase I study of panobinostat and imatinib in patients with treatment-refractory metastatic gastrointestinal stromal tumors by Bauer, S, Hilger, R A, Mühlenberg, T, Grabellus, F, Nagarajah, J, Hoiczyk, M, Reichardt, A, Ahrens, M, Reichardt, P, Grunewald, S, Scheulen, M E, Pustowka, A, Bock, E, Schuler, M, Pink, D

“…Background: Panobinostat, a pan-deacetylase inhibitor, overcomes imatinib resistance in preclinical models of gastrointestinal stromal tumours (GIST). Here we…”
Get full text

Results of a Phase I trial of sorafenib (BAY 43-9006) in combination with doxorubicin in patients with refractory solid tumors by Richly, H., Henning, B. F., Kupsch, P., Passarge, K., Grubert, M., Hilger, R. A., Christensen, O., Brendel, E., Schwartz, B., Ludwig, M., Flashar, C., Voigtmann, R., Scheulen, M. E., Seeber, S., Strumberg, D.

“…Background: Sorafenib (BAY 43-9006), a novel, oral multi-kinase inhibitor, blocks serine/threonine and receptor tyrosine kinases in the tumor and vasculature…”
Get full text

Combination of sorafenib and doxorubicin in patients with advanced hepatocellular carcinoma: Results from a phase I extension trial by Richly, H, Schultheis, B, Adamietz, I.A, Kupsch, P, Grubert, M, Hilger, R.A, Ludwig, M, Brendel, E, Christensen, O, Strumberg, D

“…Abstract Sorafenib, an oral multikinase inhibitor, shows efficacy in renal cell and hepatocellular carcinoma (HCC) and is well tolerated when combined with…”
Get full text

P1262: EZH2 INHIBITORS MEDIATE PLATINUM RESISTANCE BY ENHANCED EFFLUX by Groß, E., Hilger, R.‐A., Wehde, J., Schümann, F. L., Rohde, C., Willscher, E., Lützkendorf, J., Müller, L. P., Edemir, B., Müller, T., Binder, M., Posern, G., Weber, T.

Get full text

Dose-escalated treosulphan in combination with cyclophosphamide as a new preparative regimen for allogeneic haematopoietic stem cell transplantation in patients with an increased risk for regimen-related complications by BEELEN, D. W, TRENSCHEL, R, BAUMGART, J, PICHLMEIER, U, HAHN, J. R, HOLLER, E, CASPER, J, FREUND, M, HILGER, R. A, SCHEULEN, M. E, BASARA, N, FAUSER, A. A, HERTENSTEIN, B, MYLIUS, H. A

“…Treosulphan has recently demonstrated antileukaemic activity and potent haematopoietic stem cell toxicity. Dose-escalated treosulphan (3 x 12 or 3 x 14 g/m2)…”
Get full text

Oxaliplatin-DNA adduct formation in white blood cells of cancer patients by Pieck, A C, Drescher, A, Wiesmann, K G, Messerschmidt, J, Weber, G, Strumberg, D, Hilger, R A, Scheulen, M E, Jaehde, U

“…In this study, we investigated the kinetics of oxaliplatin-DNA adduct formation in white blood cells of cancer patients in relation to efficacy as well as…”
Get full text

The Ras-Raf-MEK-ERK pathway in the treatment of cancer by Hilger, R A, Scheulen, M E, Strumberg, D

“…The mitogen activated protein kinases (MAPKs) are conserved proteins that regulate cell growth, division and death. Although activated in the cytosol, the…”
Get more information

Results of phase I pharmacokinetic and pharmacodynamic studies of the Raf kinase inhibitor BAY 43-9006 in patients with solid tumors by Strumberg, D, Voliotis, D, Moeller, J G, Hilger, R A, Richly, H, Kredtke, S, Beling, C, Scheulen, M E, Seeber, S

Get more information

Open-label, randomized study of individualized, pharmacokinetically (PK)-guided dosing of paclitaxel combined with carboplatin or cisplatin in patients with advanced non-small-cell lung cancer (NSCLC) by Joerger, M., von Pawel, J., Kraff, S., Fischer, J.R., Eberhardt, W., Gauler, T.C., Mueller, L., Reinmuth, N., Reck, M., Kimmich, M., Mayer, F., Kopp, H.-G., Behringer, D.M., Ko, Y.-D., Hilger, R.A., Roessler, M., Kloft, C., Henrich, A., Moritz, B., Miller, M.C., Salamone, S.J., Jaehde, U.

“…Variable chemotherapy exposure may cause toxicity or lack of efficacy. This study was initiated to validate pharmacokinetically (PK)-guided paclitaxel dosing…”
Get full text

Novel antitumoral compound isolated from Clusia rosea by DIAZ-CARBALLO, D, SEEBER, S, STRUMBERG, D, HILGER, R. A

Get full text

Phase II study of nimotuzumab, a humanized monoclonal anti-epidermal growth factor receptor (EGFR) antibody, in patients with locally advanced or metastatic pancreatic cancer by Strumberg, Dirk, Schultheis, Beate, Scheulen, M. E., Hilger, R. A., Krauss, J., Marschner, N., Lordick, F., Bach, F., Reuter, D., Edler, L., Mross, K.

“…Summary Introduction Nimotuzumab is a humanized monoclonal antibody that binds to the EGFR. Based on phase I data, the recommended dose has been established at…”
Get full text

A phase I clinical and pharmacokinetic study of the raf kinase inhibitor (RKI) BAY 43-9006 administered in combination with doxorubicin in patients with solid tumors by RICHLY, H, KUPSCH, P, PASSAGE, K, GRUBERT, M, HILGER, R. A, KREDTKE, S, VOLIOTIS, D, SCHEULEN, M. E, SEEBER, S, STRUMBERG, D

Get full text

Antitumor effect and potentiation or reduction in cytotoxic drug activity in human colon carcinoma cells by the Raf kinase inhibitor (RKI) BAY 43-9006 by HEIM, M, SHARIFI, M, HILGER, R. A, SCHEULEN, M. E, SEEBER, S, STRUMBERG, D

Get full text

Reversal of MDR1-associated resistance to topotecan by PAK-200S, a new dihydropyridine analogue, in human cancer cell lines by VANHOEFER, U, MÜLLER, M. R, HILGER, R. A, LINDTNER, B, KLAASSEN, U, SCHLEUCHER, N, RUSTUM, Y. M, SEEBER, S, HARSTRICK, A

“…Recent data suggest that expression of the membrane P170-glycoprotein (P-gp) may confer resistance to the topoisomerase-I-interactive agent topotecan. The…”
Get full text

Femoral head necrosis in three patients with relapsed ovarian cancer receiving high-dose chemotherapy followed by autologous peripheral blood stem cell transplantation by BOJKO, P, HILGER, R. A, RUEHM, S. G, DIRSCH, O, SEEBER, S, SCHEULEN, M. E

“…We report three patients with relapsed ovarian cancer who developed femoral head necrosis requiring endoprosthetic hip surgery 16-35 months after high-dose…”
Get full text

Safety, tolerability and pharmacokinetic properties of the novel triazene TriN 2755 in tumour bearing dogs – a phase I study by Athanasiadi, I., Geigy, C., Hilger, R. A., Meier, V., Rohrer Bley, C.

“…TriN 2755 is an alkylating antineoplastic agent for intravenous (IV) use, carrying the triazene group as the cytotoxic principal. Using a standard 3 + 3…”
Get full text

ERK1/2 phosphorylation: a biomarker analysis within a phase I study with the new Raf kinase inhibitor BAY43-9006 by Hilger, R A, Kredke, S, Hedley, D, Moeller, J G, Bauer, R J, Stellberg, W, Seeber, S, Scheulen, M E, Strumberg, D

Get more information

Defining the role of MRP-mediated efflux and glutathione in detoxification of oxaliplatin by Mohn, C, Häcker, H-G, Hilger, R A, Gütschow, M, Jaehde, U

“…Albeit platinum complexes are widely used in cancer chemotherapy, their cellular processing has not been completely elucidated so far. In this study the…”
Get more information

The influence of liver metastases on the pharmacokinetics of doxorubicin -a population-based pharmacokinetic project of the CESAR-APOH by MÜLLER, H. J, PORT, R. E, GRUBERT, M, HILGER, R. A, SCHEULEN, M, MROSS, K

Get full text

Clinical pharmacokinetics of intravenous treosulfan in patients with advanced solid tumors by HILGER, R. A, HARSTRICK, A, EBERHARDT, W, OBERHOFF, C, SKORZEC, M, BAUMGART, J, SEEBER, S, SCHEULEN, M. E

“…Treosulfan (L-threitol- 1,4-bis-methanesulfonate, Ovastat) is a prodrug of a bifunctional alkylating agent with activity in ovarian carcinoma and other solid…”
Get full text